secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001493152-24-040288
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals launches generic Tylenol with Codeine tablets across three strengths
--------------------------------------------------------------------------------

- Launched generic acetaminophen/codeine phosphate tablets in 300mg/15mg, 300mg/30mg, 300mg/60mg.
- Product marketed under Elite Laboratories label for mild to moderate pain management.
- US market for these tablets approximated $47M for 12 months ended May 2024 (IQVIA).
- Launch expands Elite's niche generic portfolio; company operates cGMP/DEA facility in Northvale, NJ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224040288/0001493152-24-040288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224040288/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-040288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer